[Inhaled XXXX : A novel treatment for @entity2146 in psychotic disorders].

@entity1 @entity12902 @entity146 @entity148 @entity161 @entity2146 @entity2403
Psychomotor @entity2146 is a widespread clinical problem both in @entity1 with @entity161 and @entity2403 . It is a highly hazardous condition, imposing significant risks in @entity146 emergency, as expressedby elevated ratios of adverse events and traumatic experiences (both for @entity1 and medical staff). The available anti- @entity2146 drugs have numerous disadvantages. The orally administered medications (even though preferable to: @entity1 ) take hours or even-days for the therapeutic effect to emerge .(and also there is a risk of exacerbating @entity2146 in between). Although rapid onset of action (15-45 minutes) is a noteworthy merit of intramuscular drugs, such an invasive strategy is far too often bound to @entity1 ' @entity148 , resistance, and traumatic experiences. The need for novel drug formulations (ideally, both integrating the benefits of injectable and orally administered tranquillizing medications, 'and free from their disadvantages) can be, therefore, clearly grasped. Development of.inhaled @entity12902 exemplifies the attempts to overcome the above-delineated obstacles. As suggested by the available research base, inhaled @entity12902 seems to be an effective anti- @entity2146 drug in treatment of @entity1 with schizoplhenia and @entity2403 (with the onset of action similar to the one observed in intramuscular antipsychotics). However, this formulation of @entity12902 is distinguished by its non-invasive route of administration, as accompanied by markedly, low risk of side effects or adverse events.
